You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Substance Use Disorder Artificially Intelligent chatbot for screening, assessment and referral: SUD Bot

    SBC: Clinic Chat LLC            Topic: NIDA

    ABSTRACT The opioid epidemic is considered one of the most severe public health crises we are facing in the U.S. and is worsened by use of stimulants such as methamphetamine. The US Preventive Services Task Force (USPSTF) recommends screening for unhealthy drug use accompanied by offers of and referrals to services that include accurate diagnosis, effective treatment and appropriate care of a subs ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Suicide of HIV-Infected Cells by TAT-Inducible shRNA

    SBC: LENTIGEN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of the proposed project is to generate the pre-clinical data necessary to provide proof-of-principle for future clinical studies of pro-apoptotic lentiviral vector (LV) gene therapy using small hairpin RNA (shRNA) to target ?HIV-Associated Life Preserver? (HALP) and ring finger protein 7 (RNF7), two of the crucial anti- apoptotic genes in acquired HIV ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. SUPERFIBRONECTIN--A NEW ANTIMETASTATIC AGENT

    SBC: TUMOREX, INC.            Topic: N/A

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  4. SUPERFIBRONECTIN--A NEW ANTIMETASTATIC AGENT

    SBC: TUMOREX, INC.            Topic: N/A

    N/A

    STTR Phase I 1998 Department of Health and Human Services
  5. SYNTHESIS OF NEW 2(1H) QUINOLONE ANTICONVULSANT DRUGS

    SBC: Synthonics, Inc.            Topic: N/A

    N/A

    STTR Phase I 1998 Department of Health and Human Services
  6. System for documenting and tracking skin lesions

    SBC: Lumo Imaging LLC            Topic: NIBIB

    Project Summary The objective of this STTR proposal is to develop a system for longitudinally tracking the locations and morphologic changes to all Pigmented Skin Lesions on the patient’s body. The proposed software will build on a previously developed Total Body Photography (TBP) system, called Lumo Scanner, that can provide unprecedented resolution across the entire body surface. Skin cancers, ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. SYSTEMIC LYMPH NODE SPECIFIC AGENTS

    SBC: Nanopharma, Corporation            Topic: N/A

    N/A

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  8. TAPS-ESP: Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform: Technologies to Increase Screening in Primary Care to Reduce Behavioral Health Disparities

    SBC: COG ANALYTICS, LLC            Topic: 102

    ABSTRACTTAPS ESP Language accessibility and cultural awareness are essential elements of quality healthcareLimited English ProficiencyLEPindividuals are less likely to self identify a need for behavioral health serviceswhich results in longer duration of untreated disordersAccurate identificationdiagnosisand treatment are entirely dependent on a linguistically accurate screening and assessmentespe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Targeted ColQ gene therapy for Congenital Myasthenic Syndromes

    SBC: Amplo Biotechnology, Inc.            Topic: 106

    PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. TARGETED CPG OF CCR5 GENE--NOVEL HIV THERAPY

    SBC: SANGAMO BIOSCIENCES, INC.            Topic: N/A

    N/A

    STTR Phase I 1999 Department of Health and Human Services
US Flag An Official Website of the United States Government